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Neutrophils are terminally differentiated effec-
tor cells, whose principal function is to migrate 
to  sites  of  inflammation,  where  they  exert   
anti-infectious  and  proinflammatory  effects 
(Witko-Sarsat  et  al.,  2000;  Henson,  2005; 
Theilgaard-Mönch et al., 2006). However, a 
growing body of evidence shows that neutro-
phils can modulate the inflammatory process 
(Nathan, 2006). Notably, they can synthesize a 
wide variety of cytokines involved in immuno-
regulation (Cassatella, 1999). However, once 
their effector role is terminated, their tempo-
rally regulated apoptosis, followed by phago-
cytosis by tissue macrophages, is necessary for 
successful inflammation resolution (Serhan and 
Savill, 2005; Fox et al., 2010). Thus, neutrophil 
apoptosis is pivotal in inflammation resolution, 
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Neutrophil apoptosis is a highly regulated process essential for inflammation resolution,  
the molecular mechanisms of which are only partially elucidated. In this study, we describe 
a survival pathway controlled by proliferating cell nuclear antigen (PCNA), a nuclear factor 
involved in DNA replication and repairing of proliferating cells. We show that mature 
neutrophils, despite their inability to proliferate, express high levels of PCNA exclusively in 
their cytosol and constitutively associated with procaspases, presumably to prevent their 
activation. Notably, cytosolic PCNA abundance decreased during apoptosis, and increased 
during in vitro and in vivo exposure to the survival factor granulocyte colony-stimulating 
factor (G-CSF). Peptides derived from the cyclin-dependent kinase inhibitor p21, which 
compete with procaspases to bind PCNA, triggered neutrophil apoptosis thus demonstrating 
that specific modification of PCNA protein interactions affects neutrophil survival. Further-
more, PCNA overexpression rendered neutrophil-differentiated PLB985 myeloid cells sig-
nificantly more resistant to TNF-related apoptosis-inducing ligand– or gliotoxin-induced 
apoptosis. Conversely, a decrease in PCNA expression after PCNA small interfering RNA 
transfection sensitized these cells to apoptosis. Finally, a mutation in the PCNA  
interdomain-connecting loop, the binding site for many partners, significantly decreased 
the PCNA-mediated antiapoptotic effect. These results identify PCNA as a regulator of 
neutrophil lifespan, thereby highlighting a novel target to potentially modulate  
pathological inflammation.
© 2010 Witko-Sarsat et al.  This article is distributed under the terms of an At-
tribution–Noncommercial–Share Alike–No Mirror Sites license for the first six 
months after the publication date (see http://www.rupress.org/terms). After six 
months it is available under a Creative Commons License (Attribution–Noncom-
mercial–Share Alike 3.0 Unported license, as described at http://creativecommons 
.org/licenses/by-nc-sa/3.0/).
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in monocytes and lymphocytes, PCNA was located in both 
the nuclear and cytoplasmic compartments (Fig. S1, C and D), 
thus indicating that neutrophils are peculiar leukocytes in 
which PCNA is exclusively cytoplasmic.
Nuclear to cytoplasmic PCNA relocalization occurs during 
granulocyte differentiation
PCNA subcellular localization was also studied by confocal 
microscopy after PCNA immunolabeling during the course 
of in vitro granulocyte differentiation of human CD34+ cells, 
isolated from umbilical cord blood and cultured with IL-3 
and G-CSF. Complete granulocyte maturation was evaluated 
by morphological analysis after May-Grünwald Giemsa (MGG) 
staining (unpublished data). Before inducing differentiation, 
PCNA was detectable almost exclusively in the nucleus of 
CD34+ cells, whereas 7 d after IL-3–G-CSF treatment, the 
protein exhibited a mixed cytoplasmic and nuclear distri-
bution (Fig. 1 C). On day 13, most cells had multilobular 
nuclei with PCNA located in the cytoplasm, similar to that 
observed in mature peripheral neutrophils. Quantitative analy-
sis (Fig. 1 C, histograms), consisting of counting the cells 
with nuclear, cytoplasmic, or mixed nuclear–cytoplasmic 
localization, confirmed this redistribution of PCNA from 
the nucleus to the cytoplasm of differentiated neutrophils. 
This relocalization during granulocyte differentiation was 
also seen in NB4 promyelocytic cells after all-trans reti-
noic acid (ATRA)–induced differentiation into granulo-
cytes (Fig. S2). Finally, we examined PCNA localization 
in myeloid cells isolated from human BM aspirates, more 
specifically in both promyelocytes (identified by myeloper-
oxidase [MPO] immunolabeling) and mature neutrophils 
(identified by CD35 immunolabeling; Fig. 1 D). Similarly 
to that observed in granulocyte-differentiated CD34+ cells, 
PCNA was nuclear in BM granulocytic progenitors but be-
came exclusively cytoplasmic upon differentiation to mature 
neutrophils (Fig. 1 D).
PCNA is targeted to proteasomal degradation during 
neutrophil apoptosis while it is stabilized by G-CSF
As indicated by its name, the level of PCNA is modulated 
during  the  cell  cycle  and  is  particularly  high  during  the   
S phase of proliferating cells (Moldovan et al., 2007). We show   
in this study that PCNA expression also seems to be modu-
lated in nonproliferating neutrophils but as a function of 
their survival status. Indeed, PCNA expression decreased 
in apoptotic neutrophils, independently of the death path-
way, as it could be observed during constitutive and, more 
markedly, after anti-Fas– or gliotoxin-potentiated apoptosis 
(Fig. 2 A). The apoptotic process was evaluated by the degree 
of phosphatidylserine externalization (Fig. 2 B), which, as 
expected, confirmed a significant increase in annexin-V+ and 
7-aminoactinomycin D (7-AAD) cells after 15-h incubation 
at 37°C (Fig. S3 A), the increase being further enhanced 
by an anti-Fas mAb or gliotoxin. Similarly, time-dependent 
increases in caspase-8 (Fig. 2 C) and caspase-3 (Fig. 2 D) 
activities were observed in neutrophils during constitutive 
although the molecular mechanisms are not completely un-
derstood (Simon, 2003). Unlike macrophages or dendritic 
cells, neutrophils do not proliferate and have a short lifespan. 
Mcl-1 has been shown to be the main Bcl-2 homologue con-
trolling neutrophil apoptosis (Derouet et al., 2004). Yet, they 
express several cell cycle regulatory proteins, such as CDK2, 
p27 (Klausen et al., 2004), and survivin (Altznauer et al., 2004), 
which, in view of the close relationships between prolifera-
tion and apoptosis, neutrophils might use to regulate their 
own survival.
Proliferating cell nuclear antigen (PCNA) is a crucial fac-
tor in DNA synthesis and repair, initially characterized as the 
auxiliary protein of DNA polymerases  and  (Moldovan 
et al., 2007). Although all of the PCNA functions described 
to date exclusively reflect its nuclear localization, within the last 
few years, many proteins have been found to interact with 
PCNA, including various enzymes and regulatory proteins 
such  as  cyclin-dependent  kinases  (CDKs;  Koundrioukoff   
et al., 2000) or the CDK inhibitor p21/waf1 (Waga et al., 
1994). As a corollary, PCNA has been accorded roles in cel-
lular pathways other than replication, e.g., nucleotide-excision 
repair, mismatch repair, the cell cycle, and apoptosis, thus 
acting as a cellular communicator connecting all of these 
important cellular processes. In the search for additional cell 
cycle regulatory proteins expressed in neutrophils, we have 
identified an unexpected antiapoptotic role for PCNA in 
neutrophils, which, interestingly, express PCNA exclusively 
in their cytosol. Based on the knowledge that PCNA func-
tions within the nuclei of proliferating cells as a platform for 
protein interaction, we sought to characterize the molecular 
interactions between cytosolic PCNA and potential part-
ners in neutrophils. Our findings reveal that procaspases are 
novel PCNA-associated proteins and, as a result, identify 
PCNA as a new key player that positively regulates neutro-
phil survival.
RESULTS
Mature human neutrophils express PCNA exclusively  
in their cytoplasm
Western blot analysis of neutrophil lysates readily detected 
PCNA in amounts comparable with those in lymphocytes 
but less than those in the PLB985 promyelocytic cell line 
(Fig. 1 A). PCNA could be detected as a single 36-kD band in 
neutrophils and HeLa cells, using either the anti-PCNA rabbit 
pAb Ab5 or the mouse mAb PC10 (Fig. S1 A). PCNA speci-
ficity was confirmed using purified recombinant PCNA as 
an antibody competitor (Fig. S1 A). Surprisingly, subcellu-
lar fractionation of neutrophils showed high PCNA contents 
only in the cytosol and not in the nucleus or granules (Fig. 1 B). 
The quality of our fractionation procedure was validated 
by the detection of specific markers: -actin, elastase, and 
lamin B for cytosol, granules, and nuclei, respectively. Further-
more, the exclusive cytoplasmic localization of PCNA in neu-
trophils and its nuclear localization in HeLa cells were also 
illustrated by immunofluorescence labeling (Fig. S1 B). Finally, 
Western blot and confocal microscopy analysis showed that JEM VOL. 207, November 22, 2010 
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conditions used. Notably, the proteasome inhibitors PS-341 
(Fig. 2 E) and MG132 (Fig. S4 A) reversed the apoptosis-
induced PCNA degradation and, consequently, significantly 
inhibited neutrophil death. Interestingly, PS-341 also reversed 
the PCNA degradation taking place after 6-h neutrophil in-
cubation with anti-Fas mAb or gliotoxin (Fig. 2 F), implying 
apoptosis, which was again further enhanced after anti-Fas 
or gliotoxin exposure. Finally, neutrophil apoptosis was also 
demonstrated by mitochondrial depolarization after 3,3-
dihexyloxacarbocyanine iodide (DiOC6) labeling (Fig. S3 B). 
Thus, the decreased PCNA expression (Fig. 2 A) was related 
to the degree of apoptosis, regardless of the test or experimental 
Figure 1.  PCNA is expressed exclusively in the cytosol of mature neutrophils. (A) PCNA immunodetection in neutrophils (PMN), lymphocytes (Ly), 
or PLB985 promyelocytic cells. 50,000 cells/lane were analyzed using PC10 mAb as the primary antibody; anti–-actin served as the loading control.  
(B) PCNA expression in different neutrophil subcellular compartments with -actin, human neutrophil elastase, or lamin B serving as control markers for 
the cytosolic (Cyt), granular (Gr), and nuclear (Nu) fractions, respectively. The SDS–PAGE gel was run using 50 µg protein/lane, and PCNA was detected 
with the PC10 mAb. (C) Immunofluorescence analysis by confocal microscopy of PCNA localization in human CD34+ cells before (CD34+) and at different 
times (7 or 13 d) during granulocyte differentiation and in mature neutrophils using the rabbit pAb Ab5 and TO-PRO 3 iodide for nuclear labeling. Bar 
graphs show percentages of cells exhibiting nuclear, mixed nuclear–cytoplasmic, or cytoplasmic PCNA localization, as determined by counting the cells 
under the microscope. (D) Immunofluorescence analysis by confocal microscopy of PCNA localization in human BM cells after sorting on a Percoll gradi-
ent. Cells from band 3, containing myeloblasts and promyelocytes (PM; top), were labeled with MPO. In contrast, cells from band 1, containing the mature 
neutrophils as shown by their typical nuclear morphology (PMN; bottom), were labeled with anti-CD35. A–D show representative experiments of three 
yielding the same results. Bars, 10 µm.2634 PCNA prevents neutrophil apoptosis | Witko-Sarsat et al.
observed after 6-h incubation at 37°C was totally prevented 
by G-CSF, as PCNA protein levels remained elevated until 
15 h (Fig. 3 A). Such G-CSF–induced PCNA level stabiliza-
tion was dose dependent and clearly associated with pro-
longed neutrophil survival (Fig. 3 B). Incubating neutrophils 
with G-CSF for up to 21 h did not modify PCNA messenger 
RNA (mRNA) expression or transcription, as assessed by 
real-time RT-PCR and primary transcript real-time RT-
PCR, respectively, but up-regulated BLyS gene expression 
(Fig. 3 C; Scapini et al., 2003). These results were confirmed 
using different pairs of PCNA gene-specific primers, together 
with  one  of  the  four  different  housekeeping  genes:  B2m   
(2-microglobulin), GAPDH, PPIB (peptidyl-propyl isomerase B), 
that proteasome-mediated PCNA degradation occurs in both   
the death receptor and mitochondrial apoptotic pathways. 
Accordingly, PCNA is ubiquitinated in neutrophil cytosol 
after 1-h incubation at 37°C, as indicated by PCNA detec-
tion after immunoprecipitation (IP) using an antiubiquitin 
mAb (Fig. S4 B). Furthermore, chymostatin, a cathepsin in-
hibitor, had no effect on the decrease in PCNA occurring 
during constitutive neutrophil apoptosis (Fig. S4 C). The ob-
servation that PCNA levels were closely linked with neutro-
phil survival was corroborated by the stable PCNA levels 
maintained by G-CSF, which has been described as extend-
ing neutrophil longevity (Maianski et al., 2004). In fact, analy-
sis of PCNA expression kinetics revealed that the decrease 
Figure 2.  PCNA is degraded by the proteasome during neutrophil apoptosis. (A) PCNA expression kinetics in neutrophils incubated at 37°C for 1, 3, or 
15 h alone (constitutive apoptosis), with 10 ng/ml anti-Fas mAb, or with 0.1 µg/ml gliotoxin. Western blot analysis of neutrophil cytosolic fractions (50 µg/
lane) using the anti-PCNA PC10 mAb. -Actin immunoblotting served as a loading control on the same membrane. (B) Flow cytometric measurement of 
phosphatidylserine externalization on neutrophils cultured as in A and labeled with annexin-V–FITC and 7-AAD to assess apoptosis and necrosis, respectively. 
(C and D) Spectrophotometric determination of caspase-8 (C) and caspase-3 (D) activities in neutrophil lysates using their respective specific chromogenic 
IETD-pNA and DEVD-pNA substrates. (E) Effect of the proteasome inhibitor PS-341 at the indicated concentrations on survival (top) and on PCNA expression 
in neutrophils (bottom) cultured as in A. Apoptosis was obtained by incubating neutrophils at 37°C for 15 h, and neutrophil survival was evaluated as the 
percentage of annexin-V 7-AAD neutrophils, to exclude cell apoptosis and necrosis, and compared with freshly isolated neutrophils (fresh). Values are 
means ± SEM of eight independent experiments performed in duplicate (*, P < 0.05; **, P < 0.01; Student’s t test). A representative PCNA immunoblot ob-
tained under the same experimental conditions is shown on the bottom. (F) Effect of 1 µM PS-341 on PCNA expression in neutrophils incubated for 6 h at 
37°C with anti-Fas or gliotoxin and compared with freshly isolated neutrophils. The percentages of annexin-V 7-AAD neutrophils used to evaluate neutro-
phil survival were 60 and 85% in anti-Fas–treated neutrophils (without and with PS-341) and 55 and 80% in the gliotoxin-treated neutrophils (without and 
with PS-341), compared with 99% in untreated neutrophils. The bottom panel shows colloidal gold staining of the membrane used as a loading control.  
A–D and F show results from representative experiments that were performed at least four times and yielded identical results.JEM VOL. 207, November 22, 2010 
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that PCNA is associated with neutrophil survival not only 
in humans but also in mice.
A p21 peptide known to interfere with PCNA  
partners counteracts PCNA-mediated neutrophil 
antiapoptotic effects
PCNA has no intrinsic enzymatic activity as its biological 
role relies on its ability to mediate associations with different 
partners (for reviews see Warbrick, 2000; Maga and Hubscher, 
2003). Most PCNA interactions occur at the interdomain-
connecting loop. The protein with the highest currently 
known affinity for PCNA is the CDK inhibitor p21/waf1, 
which blocks the binding pocket, which explains its domi-
nant role in inhibiting cell replication and other PCNA- 
regulated functions. Therefore, we tested the effect of an 
RYIRS-tagged p21 peptide corresponding to the residues 
141–160 (so-called carboxyp21), which was previously dem-
onstrated to be able to penetrate inside the cells (Dong et al., 
2003)  and  interfere  with  PCNA  partners  in  proliferating 
cells (Warbrick, 2006). In mature neutrophils, p21/waf1 is 
barely detectable under basal conditions (Klausen et al., 
2004; unpublished data), thereby excluding its involvement 
in the regulation of cytosolic PCNA antiapoptotic activity. 
A modified carboxyp21 peptide that does not bind PCNA 
was also designed using molecular dynamic (MD) simulations 
(not depicted) and used as a control (Fig. 5 A). Immunofluo-
rescence analysis of FITC-conjugated carboxyp21 peptide–
treated neutrophils showed a strong cytoplasmic pattern of 
fluorescence (Fig. 5 B), thus confirming the efficiency of the 
cytoplasmic peptide delivery (Dong et al., 2003). Accordingly, 
carboxyp21, which is supposed to bind to PCNA and com-
pete with PCNA partners, triggered neutrophil apoptosis, as 
and GNB2L1 (guanine nucleotide–binding protein,  polypep-
tide 2-like 1; unpublished data). These observations were 
also confirmed by Northern blotting experiments (unpub-
lished data).
PCNA involvement in positively regulating neutrophil 
survival was further confirmed by examining neutrophils 
isolated from the blood of healthy donors treated with   
G-CSF for 5 d. Indeed, the PCNA content in these neutro-
phils,  assessed  by  immunoblotting,  was  markedly  higher 
than that before G-CSF treatment (Fig. 4 A). This higher 
neutrophil cytoplasmic PCNA expression in G-CSF–treated 
donors,  also  confirmed  by  confocal  microscopy  analysis 
(Fig. 4 B), was unequivocally associated with a decrease in 
the ability of these neutrophils to undergo constitutive 
apoptosis (Fig. 4 A). In keeping with the in vitro data, no 
PCNA  mRNA  induction  was  observed  in  neutrophils 
from G-CSF–treated patients, unlike what was observed for   
IL-1ra mRNA (Fig. 4 C).
To test whether PCNA could be also up-regulated dur-
ing systemic inflammation, neutrophils were isolated from 
patients with either Wegener’s granulomatosis, a necrotiz-
ing  vasculitis  associated  with  antineutrophil  cytoplasmic   
antibodies at the time of a disease flare, or with sepsis. Re-
markably, PCNA protein levels were increased in neutro-
phils isolated from both types of patients compared with 
controls (Fig. 4, D and E) without, however, any increase 
in the corresponding mRNA transcripts (Fig. 4 F). Finally, 
we also observed that mouse neutrophils isolated from ei-
ther BM or peripheral blood expressed PCNA exclusively 
within their cytoplasm (Fig. S5 A). In addition, BM neutro-
phils displayed decreased levels of both PCNA and procaspase-3 
upon apoptosis triggered by gliotoxin (Fig. S5 B), indicating 
Figure 3.  Stable PCNA protein levels are 
maintained in neutrophils exposed to  
G-CSF in vitro without transcriptional regu-
lation. (A) Neutrophils were cultured with  
and without 1,000 U/ml G-CSF at 37°C. After 
0, 3, 6, or 15 h of incubation, cells were lysed, 
and Western blot analysis was performed with 
the PC10 mAb, and anti–-actin served as the 
loading control. (B) Neutrophils were incu-
bated for 15 h at 37°C in the absence (0) or in 
the presence of 200 or 1,000 U/ml G-CSF and 
analyzed as described in A. The percentages of 
viable neutrophils, i.e., annexin-V 7-AAD 
cells under the same conditions, are shown in 
the histogram below the blot. (C) Total RNA 
was extracted from neutrophils cultured with 
and without 1,000 U/ml G-CSF for the times 
indicated, and PCNA, BLyS, and 2m mRNA 
expression was measured by real-time RT-PCR 
and primary transcript real-time RT-PCR. Their 
expression is given as mean normalized ex-
pression (MNE) after normalization to 2m in 
triplicate reactions for each sample. Error bars 
represent SEM. The data presented in A–C are 
from one representative experiment of three.2636 PCNA prevents neutrophil apoptosis | Witko-Sarsat et al.
Figure 4.  High PCNA protein levels in neutrophils isolated from G-CSF–treated donors and from patients with systemic inflammation.  
(A) Neutrophils from a representative G-CSF–treated donor were analyzed either before or during (+G-CSF) cytokine exposure, with PCNA immunode-
tected in lysates from either freshly isolated (0) or 15-h cultured cells. The percentages of viable neutrophils after culture as in Fig. 3 B are shown in the 
histogram above the blot. (B) Immunofluorescence analysis by confocal microscopy of neutrophil PCNA detected with the Ab5 pAb. Neutrophils were 
isolated from a donor before or during (+G-CSF) in vivo G-CSF treatment. Data in A and B are from one G-CSF–treated donor, representative of four dif-
ferent donors. Bars, 10 µm. (C) Total RNA was extracted from neutrophils isolated from healthy donors or G-CSF–treated patients and assayed in tripli-
cates. PCNA and IL-1ra mRNA was normalized to 2m expression and expressed as mean normalized expression (MNE) units. mRNA analysis was 
performed in three donors before and during G-CSF treatment (*, P < 0.05). (D) Representative Western blots showing neutrophil lysates prepared just 
after cell isolation from a control subject (CT) or from two patients with sepsis (SP1 and SP2) or Wegener’s granulomatosis (WG1 and WG2). (E) Densito-
metric analysis of PCNA expression in healthy subjects (CT; n = 7), patients with sepsis (SP; n = 5), and patients with Wegener’s granulomatosis (WG; n = 8). 
Data are expressed as arbitrary units (AU; means ± SEM; *, P < 0.05; Student’s t test). (F) Analysis of PCNA mRNA expression in neutrophils isolated from 
sepsis (n = 3) and Wegener’s granulomatosis (n = 5) patients or healthy donors (CT; n = 7). (C and F) Horizontal bars represent the mean value.JEM VOL. 207, November 22, 2010 
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changes, typical of neutrophil apoptosis, were 
associated with a decreased cytoplasmic PCNA 
expression  (Fig.  S6).  Moreover,  carboxyp21 
significantly  inhibited  G-CSF–induced  neu-
trophil survival (Fig. 5 F), once again strongly 
suggesting that PCNA has a regulatory role 
in neutrophil survival. Based on these find-
ings, we concluded that carboxyp21 triggers 
neutrophil apoptosis via a cell cycle–indepen-
dent mechanism, probably by competing with cytoplasmic 
PCNA partners.
PCNA overexpression delays the apoptosis induction in 
differentiated PLB985, a cellular model of neutrophils
Neutrophils  are  short-lived,  nonproliferating  primary  cells 
that are not suitable for transfection experiments. Therefore, 
promyelocytic cell lines, such as PLB985, which can differ-
entiate into neutrophils upon dimethyl-formamide (DMF) 
treatment, constitute valuable cell models mimicking mature 
neutrophils (Pedruzzi et al., 2002). As observed in NB4 cells 
indicated by higher percentages of cells with depolarized 
mitochondria after DiOC6 labeling, whereas no such activ-
ity was observed with the modified carboxyp21 peptide 
(Fig. 5 C). The proapoptotic effect of carboxyp21 was also 
demonstrated by a significantly increased percentage of cells 
with externalized phosphatidylserine after annexin-V label-
ing (Fig. 5 D). Note that carboxyp21-triggered apoptosis 
paralleled a dose-dependent decrease in PCNA expression 
(Fig. 5 E). This decreased PCNA cytoplasmic expression after 
treatment with the carboxyp21 was further confirmed using 
immunofluorescence labeling. Indeed, nuclear morphological 
Figure 5.  Potentiation of neutrophil apoptosis by 
carboxyp21, a PCNA-competing peptide. The syn-
thetic carboxyp21 and a control modified p21 peptide 
(whose charged amino acids, identified as crucial for 
binding to PCNA, were modified to prevent its binding to 
PCNA) were incubated with neutrophils to evaluate their 
effect on apoptosis. (A) Structure of PCNA (blue, red, and 
gray are used to distinguish the three monomers) bound 
to two carboxyp21 (yellow) and one modified p21 pep-
tide (green). The structure represented was obtained at 
the end of the MD simulation. The secondary structure 
elements are highlighted by a ribbon representation, and 
two different views are presented: from above the ring 
(left) and from the side (right). (B) Neutrophils were incu-
bated with 50 µM FITC-conjugated carboxyp21 peptide 
for 1 h and then analyzed by fluorescence microscopy. 
The nucleus was visualized by Hoechst staining. The pan-
els show one representative experiment of four. Bars, 5 µm. 
(C and D) Neutrophils were cultured for 6 h at 37°C alone 
or with 50 µM carboxyp21 or modified carboxyp21. The 
percentages of apoptotic neutrophils were assessed as 
depolarized mitochondria after DiOC6 labeling (C) or 
phosphatidylserine externalization after annexin-V label-
ing (D). Basal apoptosis was assessed before incubation 
(fresh). Data are means ± SEM of five independent ex-
periments (*, P < 0.05; **, P < 0.01; Student’s t test).  
(E) Neutrophils were exposed to increasing carboxyp21 
concentrations for 3 h, and apoptosis was measured by 
annexin-V labeling. The PCNA expression in the same 
samples was evaluated by Western blot analysis, and the 
bands were quantified by densitometric scanning. Data 
are from one representative experiment of four. AU, arbi-
trary unit. (F) Neutrophils were incubated with or with-
out 1,000 U/ml G-CSF in the presence or absence of  
50 µM carboxyp21 for 15 h before determining the  
percentage of apoptotic cells by annexin-V labeling. Data 
are means ± SEM of five independent experiments  
(*, P < 0.05; **, P < 0.01; Student’s t test).2638 PCNA prevents neutrophil apoptosis | Witko-Sarsat et al.
PBL985, whereas it was hardly detectable in control PLB985. 
Likewise, the cleaved caspase-3 at 17 kD was more pro-
nounced in controls as compared with PCNA-transfected 
cells showing both the 23- and 17-kD fragment. In addition, 
either mitochondrial depolarization (Fig. 6 F) or caspase-8 
activity (Fig. 6 G) was significantly lower in PLB985-PCNA 
after constitutive TRAIL- or gliotoxin-induced apoptosis com-
pared with controls.
Charge mutations in the PCNA interdomain-connecting 
loop, which is also the p21-interacting domain correspond-
ing to residues 120–132 in the PCNA sequence, were then 
used to determine whether this PCNA domain was involved 
in its antiapoptotic activity. PLB985 cells expressing an inter-
domain-connecting  loop–mutated  PCNA  were  therefore 
generated.  PCNA  antiapoptotic  activity  assessed  by  mito-
chondrial depolarization was significantly reduced in PLB985 
expressing the interdomain-connecting loop–mutated PCNA 
compared with PLB985-PCNA (Fig. 6 F). Likewise, PLB985 
stably transfected with this mutant PCNA also exhibited in-
creased  caspase-8  activity  compared  with  PLB985-PCNA   
after TRAIL- or gliotoxin-induced apoptosis (Fig. 6 G). 
In the absence of apoptotic stimulus, PCNA offered protec-
tion against differentiation-induced apoptosis, which might 
(Fig. S2), PCNA displays a nuclear to cytoplasmic relo-
calization after granulocytic differentiation (Fig. S7 A).   
Accordingly,  PLB985  cells  were  stably  transfected  with 
pcDNA3PCNA (PLB985-PCNA), as confirmed by Western 
blot analysis (Fig. 6, A and B). After DMF treatment, no dif-
ferences were observed in the expression of CD11b (Fig. S7 B) 
or in nicotinamide adenine dinucleotide phosphate (NADPH)– 
oxidase activity (Fig. S7 C). As expected, no superoxide was 
produced before differentiation, whereas significant chemi-
luminescence was triggered by PMA both in control and 
PCNA-overexpressing PLB985. Thus, PCNA overexpres-
sion did not affect granulocyte differentiation or responsive-
ness. As previously described, apoptosis could be triggered in 
PLB985 cells either via the death receptor pathway using 
TNF-related apoptosis-inducing ligand (TRAIL) or via the 
mitochondrial  pathway  using  gliotoxin  (Moriceau  et  al., 
2009). After DMF-induced differentiation, PLB985 cells 
overexpressing PCNA were protected against TRAIL- or 
gliotoxin-induced  apoptosis  compared  with  differentiated 
PLB985 transfected with the control plasmid, as judged by 
DNA fragmentation (Fig. 6 C), caspase-3 activation (Fig. 6 D), 
or chromatin condensation (Fig. 6 E). In Fig. 6 D, the pro-
caspase-3 band at 32 kD was still present in PCNA-transfected 
Figure 6.  Stable PCNA transfection pro-
tects neutrophil-differentiated PLB985 
myeloid cells from apoptosis. (A) Cytosolic 
PCNA expression in control (CT; pcDNA3-
transfected cells) and pcDNA3PCNA-transfected 
PLB985 cells, as detected by Western blot 
analysis using the Ab5 pAbs and -actin as 
loading control. (B) Quantification of PCNA 
expression after densitometry scanning  
and analysis by ImageJ software. Data are 
means ± SEM of six independent experiments  
(*, P < 0.05; Student’s t test). AU, arbitrary 
unit. (C–G) DMF-differentiated control or 
PCNA- or mutated PCNA–transfected PLB985 
cells were incubated with or without 2 µg/ml 
gliotoxin or 10 ng/ml TRAIL for 15 h to induce 
apoptosis. (C) Percentage of cells in the sub-G1 
phase showing DNA fragmentation after 
propidium iodide labeling. (D) Caspase-3  
expression by Western blot analysis in  
DMF-differentiated PLB985 cells after  
gliotoxin-induced apoptosis. Data are from 
one representative experiment that was per-
formed four times, yielding identical results. 
(E) Percentage of cells showing chromatin 
condensation after Hoechst labeling. (F) Per-
centage of cells with mitochondrial depolar-
ization after DiOC6 labeling. (G) Percentage of  
cells with caspase-8 activation using a fluo-
rescent IETD-based substrate. Data from C  
and E–G are means ± SEM of at least four 
independent experiments (*, P < 0.05;  
**, P < 0.01; Student’s t test).JEM VOL. 207, November 22, 2010 
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(Derouet et al., 2004), the expression of which decreases 
during apoptosis. Because it was previously described as a 
PCNA partner in proliferating cells (Fujise et al., 2000), we 
investigated whether PCNA could bind Mcl-1. Although 
Mcl-1 could be successfully immunoprecipitated, no physical 
association was detected between PCNA and Mcl-1 or other 
Bcl-2 homologues, e.g., the proapoptotic proteins Bax or 
Bid (unpublished data). In contrast, using the same PCNA 
co-IP protocol, procaspase-3 (Fig. 8 A), procaspase-8 (Fig. 8 B), 
procaspase-9 (Fig. 8 C), and procaspase-10 (Fig. 8 D) could 
be detected using specific mAbs. In addition, the inter-
action was confirmed in the reciprocal IP experiments using 
anti-procaspase IP and anti-PCNA for the Western blot analy-
sis (Fig. S8, A–D). Moreover, results from double immuno-
labeling with anti-PCNA and anti-procaspase performed on 
neutrophils strongly suggest that PCNA colocalizes with pro-
caspase-3, procaspase-8, procaspase-9, and procaspase-10 
(Fig. S8, A–D, right). Notably, the amount of procaspase-9 
coimmunoprecipitated  by  an  anti-PCNA  mAb  decreased 
when neutrophil cytosolic fractions were preincubated with 
the p21 peptide compared with the mutated p21 peptide 
(Fig. 8 E). The latter finding indicates that the p21 peptide 
displaces the procaspase-9–PCNA interaction, which in turn 
suggests that the interconnecting loop domain is involved in 
the interaction between PCNA and procaspase-9. To further 
validate such a hypothesis, caspase-9 activation was investi-
gated in PLB985 cells overexpressing PCNA or the inter-
domain-connecting loop–deficient PCNA mutant. After 5 d 
of DMF exposure, the caspase-9 activity was elevated in 
contrast to undifferentiated cells. This caspase-9 activity 
corresponds to physiological apoptosis of aged neutrophils. 
Notably, this differentiation-induced caspase-9 activation 
was significantly lower in PLB985-PCNA than in control 
PLB985 cells, thus confirming the antiapoptotic effect of 
PCNA. In contrast, no protective effect against differentiation-
induced apoptosis was observed in PLB985 cells express-
ing the mutant PCNA (Fig. 8 F). Collectively, our findings 
strongly  suggest  that  the  interdomain-connecting  loop   
is involved in the PCNA–procaspase-9 interaction. There-
fore, we hypothesized that the cytosolic PCNA–procaspase 
reflect physiological neutrophil apoptosis. However, the 
mutated PCNA had roughly the same antiapoptotic effect, 
thus suggesting that in this case, PCNA domains other than 
that of the interdomain-connecting loop might also be im-
portant in the PCNA antiapoptotic effect. Collectively, these 
findings strongly suggest that some PCNA protein partners 
could bind to the PCNA interdomain-connecting loop to 
mediate the observed antiapoptotic effect. These observa-
tions also corroborate the results showing that carboxyp21 
triggered neutrophil apoptosis by binding specifically to this 
PCNA site.
PCNA small interfering RNA (siRNA) sensitized  
DMF-differentiated PLB985 to apoptosis
In a final series of experiments, PLB985 cells were stably 
transfected with PCNA siRNA to knock down PCNA gene 
expression, as confirmed by Western blot analysis (Fig. 7,   
A and B). Notably, the siRNA procedure was performed on 
days 3 and 4 after DMF treatment, before analysis of the 
apoptosis rate on day 5. At this time point, all PCNA was cy-
toplasmic in DMF-differentiated PLB985 cells (Fig. S7 A). 
No effect of PCNA siRNA was observed on CD11b expres-
sion (66.5 ± 7.7% vs. 60.9 ± 6.3% CD11b-expressing PLB985 
cells for scrambled and PCNA siRNA, respectively), thus 
suggesting that it did not affect the differentiation process. 
PCNA siRNA but not scrambled siRNA slightly but signifi-
cantly enhanced the constitutive apoptosis that PLB985 cells 
undergo after differentiation, as assessed by mitochondria 
depolarization (Fig. 7 C). Moreover, PCNA siRNA also   
dramatically potentiated the gliotoxin- or TRAIL-induced 
apoptosis of PLB985 cells (Fig. 7 C), further supporting the 
antiapoptotic activity of PCNA.
PCNA associates with procaspase-3, procaspase-8, 
procaspase-10, and procaspase-9 and interferes  
with activation of the latter
Finally, we performed co-IP experiments using neutrophil 
cytosols to identify potential cytosolic PCNA partners, which 
could contribute to its antiapoptotic activity. Mcl-1 is one of 
the most important Bcl-2 homologues expressed in neutrophils 
Figure 7.  Knocking down PCNA expres-
sion by siRNA sensitizes DMF-differentiated 
PLB985 cells to apoptosis. DMF-differentiated 
PLB985 cells were transfected twice with 
control (CT) siRNA or with PCNA siRNA on 
days 3 and 4 after DMF. (A) Cytosolic PCNA 
expression was evaluated by Western blot 
analysis using the Ab5 pAb (-actin expres-
sion was used as loading control). (B) Quanti-
fication of PCNA expression by densitometric 
scanning using ImageJ software. Data are 
means ± SEM of six independent experiments 
(*, P < 0.05; Student’s t test). (C) Effect of 
PCNA siRNA on the percentage of apoptotic PLB985 cells as measured by mitochondrial depolarization after DiOC6 labeling. PLB985 cells were incubated 
with 2 µg/ml gliotoxin (n = 6), 10 ng/ml TRAIL (n = 5), or in basal conditions (n = 10) for 15 h. Data are means ± SEM of n independent experiments (*, P < 0.05; 
**, P < 0.01; Student’s t test).2640 PCNA prevents neutrophil apoptosis | Witko-Sarsat et al.
levels (Fig. 9 C, right) showed an impaired capacity to activate 
procaspase-9 in vitro as compared with cytosols from control 
neutrophils (Fig. 9 C, left).
DISCUSSION
Regulation of the neutrophil lifespan provides a fine balance 
between their function as host defense effector cells and a safe 
turnover of these potentially harmful cells. Neutrophil apop-
tosis is essential for the resolution of inflammation, and de-
layed apoptosis and compromised neutrophil clearance are, in 
fact, hallmarks of chronic inflammation (Simon, 2003; Fox   
et al., 2010). Therefore, the neutrophil has a carefully orches-
trated lifespan, which requires the intervention of a pre- 
established intracellular clock with successive steps and key 
control points, which are still undefined.
In this study, we have discovered that PCNA, a well-
known nuclear protein involved in DNA replication and re-
pair and considered one of the central molecules responsible 
for the life or death decision in proliferating cells only   
(Moldovan et al., 2007), displays all of the features of a master 
interaction might prevent their activation. This was tested 
by evaluating procaspase-9 cleavage in an in vitro assay, using 
neutrophil cytosol containing the apoptosome components, 
i.e., procaspase-9 and Apaf-1 (apoptotic protease-activating 
factor 1), as previously described (McStay et al., 2008). 
The addition of exogenous purified cytochrome c and dATP 
triggered procaspase-9 cleavage (37 kD) in a time-dependent 
manner, as indicated by Western blot analysis of caspase-9 
(Fig. 9 A). However, when purified recombinant PCNA was 
added to the mixture, procaspase-9 cleavage was delayed, 
with maintained levels of the 46-kD fragment of procas-
pase-9 but reduced 37-kD fragment detection, thus demon-
strating that purified PCNA impairs procaspase-9 activation. 
Ovalbumin tested at the same concentration did not affect 
procaspase-9 activation and thus served as a control (unpub-
lished data). Notably, PCNA was also cleaved in parallel with 
the activation of caspase-9 (Fig. 9 B), thus explaining why the 
inhibitory effect on procaspase-9 activation by PCNA de-
creases with the time. Finally, cytosols from neutrophils iso-
lated from G-CSF–treated donors that contained high PCNA 
Figure 8.  Co-IP experiments identify procaspase-3, procaspase-8, procaspase-9, and procaspase-10 as PCNA partners. Co-IP experiments  
were performed using neutrophil cytosol. Unbound material (UB) and bound (B) immunoprecipitated proteins were analyzed by Western blot analysis.  
(A–D) In IP, PCNA pAb (IP PCNA) or empty beads (IP control) were used, whereas in Western blot analysis, PC10 anti-PCNA was used (to ascertain the pres-
ence of PCNA) together with one of the following: anti–procaspase-3 mAb (A), anti–procaspase-8 mAb (B), anti–procaspase-9 mAb (C), or anti–procaspase-10 
mAb (D). (E) Co-IP experiments performed as in C using PCNA containing neutrophil cytosol incubated with 100 µM carboxyp21 or the mutated p21 peptide 
(used as a control). Both unbound material and bound immunoprecipitated proteins were analyzed by Western blot analysis using anti–procaspase-9  
and anti-PCNA (PC10). A–E show data from representative experiments that were performed at least four times, yielding identical results. (F) Caspase-9 
activity in PLB985 cells overexpressing wild-type or mutated PCNA compared with controls (CT). CD11b+–caspase-9+ cells were measured by flow cytometry 
before and after DMF-induced differentiation. Data are means ± SEM of four independent experiments (**, P < 0.01; Student’s t test).JEM VOL. 207, November 22, 2010 
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(Roa et al., 2008). Similarly, it is currently unknown whether 
or not cytoplasmic PCNA is associated with the survival of 
differentiated cells from nonmyeloid origin.
According to numerous studies, PCNA functions in the 
nucleus as a remarkable adaptor molecule that binds to numer-
ous proteins (for review see Warbrick, 2000). Indeed, several 
authors have established that trimeric PCNA plays a central 
role as a moving platform along the DNA molecule (for re-
view see Maga and Hubscher, 2003), which acts as a commu-
nication center for a variety of cell nuclear processes, such as 
DNA replication, nucleotide excision repair, postreplication 
mismatch repair and apoptosis. Therefore, it is clear that 
one key to understanding the molecular mechanisms whereby 
PCNA exerts its antiapoptotic activity in neutrophils is to 
identify its partners. However, in noncycling cells such as neu-
trophils, PCNA antiapoptotic activity should theoretically 
proceed via mechanisms not involving any nuclear function. 
Indeed, one salient feature revealed in our study was the exclu-
sive localization of PCNA in the neutrophil cytosol, and we 
documented its nucleus to cytosol relocalization in the later 
stages of neutrophil maturation. The underlying mechanisms, 
either in terms of nucleocytoplasmic transport or sequestration 
mechanisms to retain PCNA within the cytoplasm compart-
ment, remain to be deciphered. Notably, we have clearly dem-
onstrated that in primary neutrophils, PCNA is constitutively 
associated with procaspase-3, procaspase-8, procaspase-9, and 
procaspase-10, presumably sequestering them within the cyto-
sol to prevent their activation. How such interactions occur at 
the molecular level remains to be elucidated, but it can be 
foreseen that posttranslational modifications of PCNA, e.g., 
acetylation, phosphorylation (Naryzhny and Lee, 2004), or su-
moylation (Moldovan et al., 2007), already described in other 
cell types could regulate PCNA association with its neutrophil 
regulator of neutrophil survival. Indeed, we observed that   
although circulating mature neutrophils contain elevated 
amounts  of  PCNA,  their  PCNA  contents  change  as  a 
function of their viability status. In neutrophils undergo-
ing apoptosis, PCNA was subjected to proteasome-mediated 
degradation, regardless of whether the trigger signaling cas-
cade passed through the extrinsic (death receptors) or the in-
trinsic  pathway  (mitochondria).  Although  the  proteasome 
seems to play a pivotal role in PCNA degradation, other pro-
teolytic pathways might be involved to modulate PCNA   
levels during apoptosis.
In contrast, PCNA levels are stably maintained by factors 
that prolong neutrophil survival, e.g., G-CSF. Notably, 
modulation of PCNA contents, at least in human neutro-
phils, appears to involve only posttranscriptional events be-
cause variations in PCNA mRNA expression were not 
detected during in vitro or in vivo G-CSF treatment. In ad-
dition, neutrophils isolated from G-CSF–treated donors ex-
hibited both prolonged survival, as previously described (Basu 
et al., 2002), and also high PCNA contents, in keeping with 
the major role of PCNA in neutrophil survival. PCNA gene 
induction has not been reported to occur in neutrophils iso-
lated from donors treated with G-CSF in vivo (Drewniak   
et al., 2009), which is consistent with our findings. Further-
more, PCNA levels in neutrophils isolated from patients with 
sepsis or necrotizing vasculitis were much higher than those 
isolated from healthy individuals, and no PCNA mRNA up-
regulation was observed. These findings support the notion 
that neutrophil PCNA levels vary during systemic inflamma-
tion related (sepsis) or not (Wegener’s granulomatosis) to an 
infection. Whether or not cytoplasmic PCNA is absolutely 
required for neutrophil survival cannot, at present, be ex-
plored because of the lack of viable PCNA knockout animals 
Figure 9.  PCNA impaired pro–caspase-9 activation in vitro. (A) Kinetics of immunodetection of cleaved caspase-9 after an in vitro procaspase-9 
activation assay performed using neutrophil cytosol, 50 µM cytochrome c, and 1 mM ATP, without and with 50 µM recombinant PCNA. (B) Kinetics of 
PCNA immunodetection using PCNA pAb performed in the same in vitro assay as in A in the absence of exogenous recombinant PCNA to detect only 
endogenous PCNA. (C) Kinetics of cleaved caspase-9 immunodetection as in A in cytosol of neutrophils isolated from G-CSF–treated donors or controls 
(CT). PCNA Western blot analysis confirmed higher PCNA levels in the G-CSF–treated donors (right). A–C show data from representative experiments that 
were performed at least four times, yielding identical results.2642 PCNA prevents neutrophil apoptosis | Witko-Sarsat et al.
high levels of CDK2 and the CDK inhibitor p27 (Klausen et al., 
2004). Indeed, during inflammation, neutrophils are able to up-
regulate survivin, a member of the IAP (inhibitor of apoptosis 
protein) family, which acts as a link between apoptosis and con-
trol of mitogenic progression in proliferating cells (Altznauer 
et al., 2004). Thus, it becomes increasingly apparent that cell 
cycle regulatory proteins other than PCNA might be implicated 
in controlling neutrophil lifespan.
Most studies on neutrophils, viewed as potential cellular 
targets in inflammation, attempted to block their migration 
and influx. However, another aspect of neutrophil biology 
that could be targeted, albeit often underestimated, is the 
modulation of neutrophil survival (Hallett et al., 2008).   
In this regard, an in-depth understanding of the specific and 
highly regulated molecular mechanisms controlling neutro-
phil survival/death is required to intervene efficiently and ef-
fectively. The results reported in this paper are notable, not 
only because they demonstrate that PCNA acts as a cytoplas-
mic platform pulling the strings of neutrophil survival, but 
also because they reveal new ways of thinking about neutro-
phils and their intracellular pathways in the context of in-
flammation or neutropenia.
MATERIALS AND METHODS
Blood and BM cell isolation, differentiation of CD34+ precursors, 
and cell culture. Blood or BM donors gave their written informed con-
sent to participate in this study, which was approved by the Institut Na-
tional de la Santé et de la Recherche Médicale Institutional Review Board 
and the Ethics Committee of Hôpital Necker-Enfants Malades and Hôpital 
Cochin (Paris, France). Human neutrophils from healthy (Etablissement 
Français du Sang, Paris, France) or G-CSF–treated healthy donors (10 µg/kg 
for  5  d  to  induce  hematopoietic  stem  cell  mobilization;  Service  de   
Biothérapie, Hôpital Necker-Enfants Malades) were isolated from EDTA- 
anticoagulated blood, using density-gradient centrifugation through Poly-
morphprep (Nycomed). Neutrophils were isolated from the blood of 
vasculitis and septic patients hospitalized in the Service de Médecine   
Interne, Hôpital Cochin. Patients with sepsis (n = 5) had documented 
gram-positive  or  -negative  infection,  body  temperature  >38.5°C,  and   
C-reactive protein >100 mg/ml. Patients with antineutrophil cytoplasmic 
antibody–associated vasculitis (n = 8) fulfilled the criteria for Wegener’s 
granulomatosis (Leavitt et al., 1990). They had anti–proteinase 3 antibodies 
and active disease, as assessed by a Birmingham vasculitis activity score of ≥3 
(Luqmani et al., 1994). Neutrophil subcellular fractionation was performed 
to obtain separate cytosolic, granular, and nuclear fractions, as previously 
described (Borregaard et al., 1983). BM cell separation was performed   
by Percoll gradient centrifugation as previously described (Cowland and 
Borregaard, 1999). Monocytes and lymphocytes were isolated on Ficoll 
gradient as previously described (Kantari et al., 2007). Differentiation of 
CD34+ cells into granulocytes was induced as previously described (Hino et al., 
2000), with some minor modifications. In brief, CD34+ cells were isolated 
from cord blood and then cultured with 10 ng/ml stem cell factor, 10 ng/ml 
IL-3, and 100 ng/ml IL-6 for 7 d. CD36 cells were isolated and then in-
cubated with 10 ng/ml G-CSF, 100 ng/ml stem cell factor, and 10 ng/ml 
IL-3 for 13 d to promote granulocyte differentiation. MGG staining was 
used at different times to monitor differentiation. Peripheral blood neutro-
phils and mature neutrophils from femur BM were isolated using a Percoll 
density gradient as previously described (Mócsai et al., 2002).
HeLa, PLB985, and NB4 promyelocytic cell lines were cultured in 
RPMI supplemented with 10% fetal calf serum. NB4 cells were induced to 
differentiate with 1 µM ATRA (Sigma-Aldrich) for 5 d, and granulocyte 
differentiation was validated by CD11b expression and by morphological 
partners. Notably, neutrophils contain extremely low amounts 
of cytochrome c but exhibit high Apaf-1 levels and very high 
caspase-9 activity during physiological apoptosis (Murphy et al., 
2003). Thus, procaspase-9 sequestration by PCNA seems to be 
a very efficient way to inhibit apoptosis. Accordingly, in vitro 
procaspase-9 activation was delayed either by adding exogenous 
recombinant PCNA or in neutrophil cytosol from G-CSF–
treated donors containing high PCNA levels. However, we 
cannot exclude that association with other cytoplasmic proteins 
might mediate the antiapoptotic effect of PCNA in neutrophils.
In proliferating cells, PCNA is strongly controlled by the 
tumor suppressor protein p21/waf1, which was initially identi-
fied as a potent CDK inhibitor (Waga et al., 1994). Structural 
experiments indicated that p21/waf1 directly blocks the sur-
face  region  required  for  polymerase  binding  (Waga  et  al., 
1994). Biochemical experiments broadened that concept by 
showing that p21/waf1 is an effective competitor for other 
PCNA partners (Warbrick, 2006). Indeed, synthetic peptides 
carrying the consensus sequence for binding to the PCNA 
interdomain-connecting loop, such as the carboxyp21 peptide 
(residues 120–132 on the PCNA sequence) used in our study, 
stop progression through the cell cycle and induce apoptosis 
when transfected into proliferating cells (Dong et al., 2003). 
We have shown that carboxyp21 (a) directly triggers neutrophil 
apoptosis and concomitant PCNA degradation and (b) impairs 
the capacity of G-CSF to prolong neutrophil survival, thus 
clearly proving that PCNA is absolutely essential for the 
G-CSF antiapoptotic effect in neutrophils. Previous in vitro 
studies have shown that the C-terminal region of p21, which 
contains  the  PCNA-interacting  domain,  can  competitively 
block the reassociation of the polymerase complex with PCNA 
in proliferating cells (Mattock et al., 2001b; Warbrick, 2006). 
However, the carboxyp21 peptide also contains 4 aa at the 
C terminus that function as a site for CDK association, thus 
suggesting that its effect might be caused by CDK inhibi-
tion (Mattock et al., 2001a). However, in this study, we show 
that a p21 peptide mutated at the PCNA-interacting domain, 
with an intact CDK-interacting domain at the C terminus, does 
not display the same degree of apoptosis potentiation observed 
with the wild-type p21 peptide. Therefore, even if the p21 
peptide might theoretically promote apoptosis via CDK inhi-
bition at higher concentrations, we concluded that in neutro-
phils, the effect of the p21 peptide, at least at the concentrations 
that we have tested, is mainly caused by its binding to PCNA.
Interestingly, inhibition of CDK by the synthetic inhibitor 
roscovitine triggers neutrophil apoptosis and, consequentially, 
promotes inflammation resolution in vivo (Rossi et al., 2006). 
Thus, these authors have provided evidence that CDK activities, 
so far restricted to cell cycle regulation, can control apoptosis in 
nonproliferating cells like neutrophils. Roscovitine has also been 
shown  to  improve  the  resolution  of  the  inflammation  after 
pneumococcal infection and accelerated recovery (Koedel et al., 
2009) and to reverse the late apoptosis observed in neutrophils 
from cystic fibrosis patients (Moriceau et al., 2010). Further-
more, although several cell cycle proteins are down-regulated 
during neutrophil differentiation, mature neutrophils expressed JEM VOL. 207, November 22, 2010 
Article
2643
study its subcellular localization. Neutrophils were incubated for 1 h with 
the fluorescent peptide (at the indicated concentrations) and were induced to 
adhere on poly-l-lysine–precoated coverslips as previously described (Kantari 
et al., 2007). Fluorescence microscopy was performed with a microscope 
(DMRD; Leica) and a camera (model DP11P; Olympus). The effects of   
PS-341 (LC Laboratories) and MG132 were tested on neutrophil apoptosis 
and PCNA expression.
Real-time  RT-PCR  and  primary  transcript  real-time  RT-PCR. 
Real-time RT-PCR and primary transcript real-time RT-PCR were per-
formed as described by Tamassia et al. (2008) using gene-specific primer 
pairs (Invitrogen) available in the public database RTPrimerDB under the 
following entry codes: human PCNA (7839), PT-PCNA (7840), BLyS/
TNFSF13B (7841), PT-BLyS (7842), IL-1ra (3544), GAPDH (3539), PPIB 
(7786), GNB2L1 (8211), and 2m (3534). The reaction conditions were 
identical for all primer sets, as follows: 50°C for 2 min, 95°C for 2 min, and 
then 40 cycles of 95°C for 15 s and 60°C for 1 min. 2m was chosen as a 
normalizing gene because of its stable expression levels in leukocytes. The 
data were analyzed with QGene software and are expressed as mean expres-
sion units after 2m normalization. The same RNA samples were processed 
in the absence of RT and served as controls for genomic DNA contamina-
tion. Northern blot analysis was conducted as previously described (Rossato 
et al., 2007).
Plasmid vector construction and recombinant PCNA expression. 
Recombinant  PCNA  was  produced  in  Escherichia  coli  using  the  plasmid 
PETPCNA containing the human PCNA cDNA (gift from B. Stillman, 
Cold Spring Harbor Laboratory, Cold Spring Harbor, NY) and purified as 
previously described (Waga et al., 1994). To obtain PCNA overexpression 
in PLB985 cells, PCNA cDNA was subcloned into the expression vector 
pCDNA3/neo (Invitrogen) between the HindII and NotI restriction sites. 
Site-directed mutagenesis was performed using the QuikChange method 
(Agilent Technologies) to obtain PCNA mutated on charged amino acids 
within the known p21-interacting sequence located at the interdomain- 
connecting loop (PCNA–D120A–D122A–E124A–E130A–E132A). All 
cDNA sequences were confirmed by direct sequencing. PLB985 cells were 
transfected using the Amaxa system (Lonza), according to the manufacturer’s 
instructions. In brief, 2 × 106 cells were resuspended in 100 µl of cell line so-
lution with 1 µg of plasmid (control pcDNA3–neomycin, pcDNA3–PCNA, 
or pcDNA3–mutated PCNA). The cells were then electroporated and trans-
ferred to culture plates. Transfected cells were cloned and selected based on 
their resistance to 1 mg/ml neomycin.
For PCNA siRNA experiments, PLB985 cells were treated with DMF 
to induce granulocytic differentiation and transfected with 1 µM siRNA 
(Applied Biosystems) twice at a 24-h interval (day 3 and day 4 after DMF 
treatment) using the Amaxa system as described in the previous paragraph. 
FITC-conjugated control siRNA, used to detect intracellular siRNA by 
flow cytometry and to monitor transfection efficiency, showed that the 
fluorescent siRNA was taken up in >90% of the PLB985 cells. Constitu-
tive, gliotoxin- and TRAIL-induced apoptosis was evaluated by mito-
chondria depolarization after DiOC6 labeling after gating on CD11b+ cells 
after control scrambled siRNA and PCNA siRNA transfection. PLB985 
cells transfected with specific PCNA siRNA or control siRNA were also 
lysed to analyze PCNA expression by Western blotting using the rabbit 
anti-PCNA pAb.
Western blot analysis and co-IP experiments. Neutrophils were soni-
cated, and cytosolic proteins were analyzed using either the PC10 mAb or 
the Ab5 pAb anti-PCNA, according to standard immunoblot procedures 
(Moriceau et al., 2009). Co-IP experiments were performed using neutro-
phil cytosols obtained by cavitation (Borregaard et al., 1983). 500 µg cytosol 
was mixed with 50 µl protein G and Ab5 pAb and incubated for 30 min at 
4°C under shaking. The sample was loaded onto a column containing   
Sepharose-coated magnetic beads (Miltenyi Biotec) and washed with a 
stringent washing buffer (50 mM Tris, 500 mM NaCl, 1% NP-40, and 
analysis after MGG staining. PLB985 cell granulocyte differentiation was   
induced by exposure to 0.5% DMF for 5 d and validated as for NB4. 
Functional  analysis  of  NADPH-oxidase  activity  was  performed  with   
lucigenin-amplified chemiluminescence in a single-photon luminometer   
(AutoLumat LB953; Berthold Technologies). The chemiluminogenic sub-
strate, lucigenin (10,10-dimethyl-9,9-biacridium dinitrate), was used to se-
lectively  measure  NADPH-oxidase–dependent  extracellular  superoxide 
anion formation. In brief, 100 µl containing 5 × 105 cells, neutrophils, or 
PLB985 cells was placed in polystyrene tubes containing 100 µl of 0.2 mM 
lucigenin and 50 µl of stimulus, either HBSS or PMA (16 µM final concen-
tration). The luminescence was measured in duplicate and expressed as inte-
grated total counts in 40 min.
Immunofluorescence  labeling  and  confocal  microscopy  analysis. 
Immunolabeling of neutrophils, HeLa, CD34+, PLB985, or NB4 cells to 
study PCNA subcellular localization was performed as previously described 
(Kantari et al., 2007). Cells were fixed in PBS containing 3.7% formaldehyde 
(Sigma-Aldrich) for 20 min on ice and permeabilized with 0.25% Triton   
X-100 for 5 min at room temperature, followed by ice-cold methanol for   
10 min, incubated with rabbit pAb diluted 1:25 (Ab5; EMD) for 45 min, 
followed by biotinylated rabbit IgG diluted 1:100 (Dako) for 30 min, and 
then by streptavidin-coupled Alexa Fluor 555 diluted 1:200 (Invitrogen) for 
30 min. The nuclei were stained with TO-PRO 3 iodide (10 µM solution; 
Invitrogen) or with 5 µg/ml Hoechst (Sigma-Aldrich) for 30 min. For colo-
calization with PCNA, anti-CD35 (mouse IgG1; clone J3D3; diluted 1:50; 
Beckman Coulter) or anti-MPO (mouse IgG2a; clone MPO-7.17; dilution 
1:200; PeliCluster; Red Cross; diluted 1:100) or anti–procaspase-8 (EMD), 
anti–procaspase-3, or anti–procaspase-9 or anti–procaspase-10 (Santa Cruz 
Biotechnology, Inc.) mAbs were used as primary antibodies, followed by an 
Alexa Fluor 488–conjugated anti–mouse mAb (diluted 1:100; Invitrogen). 
Slides were analyzed by confocal microscopy with a confocal scanning laser 
microscope (LSM-5 version 3.2 SP2; Carl Zeiss, Inc.) equipped with an 
argon laser and helium–neon lasers using a Plan-Apochromat 63× NA 1.40 
oil immersion objective lens at room temperature. Green fluorescence was 
observed with a 505–530-nm band-pass emission filter under 488-nm laser   
illumination, and red fluorescence was observed with a 488–560-nm-long-pass 
emission filter under 543-nm laser illumination. Pinhole diameters were set 
to get 0.8-µm-thick optical slices, and images were collected every 0.4 µm 
along the z axis. Imaging of Alexa Fluor 488, Alexa Fluor 555, Hoechst, and 
TO-PRO 3 iodide fluorescence was obtained using the multitrack mode. 
The  fluorescence  was  analyzed  using  ImageJ  software  version  1.42d   
(National Institutes of Health).
Analysis of apoptosis. Neutrophil apoptosis was triggered by incubating 
neutrophils at 37°C alone (constitutive apoptosis) or with 10 ng/ml anti-Fas 
mAbs (Beckman Coulter) or 0.1 µg/ml gliotoxin (Sigma-Aldrich; Ward   
et al., 1999) for the indicated times. Neutrophil apoptosis was evaluated   
using phosphatidylserine externalization after annexin-V and 7-AAD label-
ing (Kantari et al., 2007), mitochondrial depolarization after DiOC6 labeling 
(Moriceau et al., 2009), and by caspase-3 and caspase-8 activities measured 
by spectrophotometry (BioVision) in neutrophil lysates. In DMF-differentiated 
PLB985 cells, apoptosis was triggered by 2 µg/ml gliotoxin or by 10 ng/ml 
recombinant TRAIL (R&D Systems; Yin et al., 2005), and caspase-8 and 
caspase-9 activities were determined after gating on CD11b+ cells using the 
Caspase-Glow assay (Promega). Apoptosis-induced chromatin condensation 
and DNA fragmentation were assessed after DNA staining with 5 µg/ml of 
the blue fluorescent dye Hoechst and propidium-iodide staining, respec-
tively (Goepel et al., 2004). Carboxyp21 (KRRQTSMTDFYHSKRRLIF-
SRYIRS) corresponding to the p21/waf1 C terminus sequence (residues 
141–160) and containing a RYIRS C-terminal extension to facilitate its cell 
entry, as previously demonstrated (Dong et al., 2003), was synthesized and 
purified (GeneCust). A modified peptide, in which the charged amino acids 
responsible for its binding to PCNA have been changed according to dy-
namic simulation experiments (KRRQTGETDFDHAKAALIFSRYIRS), 
served as control. An FITC-conjugated carboxyp21 peptide was used to 2644 PCNA prevents neutrophil apoptosis | Witko-Sarsat et al.
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